{"schema_version":"secwatch.filing_event.v1","accession":"0001520138-22-000553","form_type":"8-K","ticker":"BIVI","cik":"0001580149","company_name":"BIOVIE INC.","filed_at":"2022-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.263492+00:00","generated_at":"2026-06-21T08:08:17.189443+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioVie reports positive NE3107 data in Parkinson's, Alzheimer's, and aging biomarkers","bullets":["NE3107+levodopa improved UPDRS Part 3 by 3+ points vs levodopa alone at 2-3 hours (clinically meaningful); 6+ points for patients <70.","NE3107 improved cognition: ADAS-Cog12 +2.2 points (p=0.0173), CDR +0.11 (p=0.0416), ADCOMS +0.07 (p=0.0094) in mild cognitive impairment/mild AD.","NE3107 reduced Horvath DNA methylation SkinBlood clock by 3.3 years (p=0.0021) after 3 months; 19 of 22 patients showed reduction.","BioVie increased Phase 3 AD trial enrollment from 316 to 400; topline results expected before end of Q3 2023.","Company plans to discuss Phase 3 Parkinson's program with FDA and expects to launch Phase 3 trials in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001520138-22-000553","json":"https://secwatch.observer/filing/0001520138-22-000553.json","markdown":"https://secwatch.observer/filing/0001520138-22-000553.md","text":"https://secwatch.observer/filing/0001520138-22-000553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580149/000152013822000553/0001520138-22-000553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580149/000152013822000553/bivi-20221207_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:08:17.189443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}